The use of real world data to assess the safety and effectiveness of drugs and medical treatments is among the most controversial topics in medicine. As chief executive of Aetion, a New York City startup that sells software to analyze those data, Carolyn Magill is in the middle of the fray — one whose outcome will have a huge impact on how medicines are studied and priced in the future.

During an interview with STAT at last week’s Health Datapalooza conference in Washington, D.C., the former insurance executive passionately made the case that analyzing real world data is crucial for incorporating patient experiences into decision-making by drug companies, insurers, providers, and regulators.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy